Topic: non-small cell lung cancer
Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.
Despite Regeneron's rhetoric, analysts are pessimistic about growth prospects for its I-O drug Libtayo and new trial data didn't calm their fears.
Wall Street analysts pressed Merck for details about whether Keytruda can maintain strong growth as it faces rivals in lung and breast cancer.
After watching from the sidelines as its rivals dove into I-O’s most coveted market, AstraZeneca finally has a win in previously untreated NSCLC.
Tagrisso, Lynparza and Imfinzi, as well as China, have teamed up for growth at AstraZeneca. But each faces its own fight just around the corner.
It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.
Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact."
Adding Cyramza to Roche’s Tarceva stalled tumor progression by 19.4 months, a seven-month improvement over Tarceva alone.
Right now, Merck’s Keytruda is the only I-O treatment approved solo in previously untreated NSCLC. But Roche’s Tecentriq is looking to make it two.
Roche has been looking to capture lung cancer share from Merck with its chemo combo. And it's trying to bring its quest to the monotherapy arena, too.